EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor

Shailly Mehrotra, Yasuyo Sano, Petro Halkowycz, Elizabeth Wilson, Chandra Durairaj, Kok-Fai Kong, Guliang Xia, Faith Dunbar, Taylor Spector, Graham A Heap, Christopher G Bunick, Iain B McInnes

Journal of Investigative Dermatology · 2026-01 · 146 (1) · 214-222.e7

DOI: 10.1016/j.jid.2025.05.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2026-01. Verfasst von Shailly Mehrotra und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative Clinical Pharmacology, Takeda Development Center Americas, Cambridge, Massachusetts, USA. Electronic address: shailly.mehr…. Hauptthemen laut MEDLINE: TYK2 Kinase, Protein Kinase Inhibitors, Benzamides. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals America Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zasocitinib (TAK-279) is an investigational, oral, highly selective, and potent allosteric TYK2 inhibitor. This study assessed the TYK2 inhibitory selectivity and potency of zasocitinib versus those of licensed TYK2 and Jak inhibitors. Binding affinities were determined using homogenous time-resolved fluorescence. In vitro concentration-percentage inhibition curves for IL-23-phosphorylated signal transducer and activator of transcription (pSTAT)3, type I IFN-pSTAT3, IL-12-pSTAT4, IL-2-pSTAT5, and thrombopoietin-pSTAT3 pathways were established using human whole-blood assays. Relationships between concentration and percentage inhibition were determined to estimate half-maximal inhibitory concentration. Times above half-maximal inhibitory concentration and percentage daily inhibition were modeled from simulated clinical concentrations. Zasocitinib bound the TYK2 Janus homology 2 domain with an inhibitory constant of 0.0087 nM, demonstrating more than 1 millionfold selectivity over Jak1. Zasocitinib potently inhibited TYK2 signaling, with half-maximal inhibitory concentrations of 48.2 nM (95% confidence interval = 36.8-63.1 nM), 21.6 nM (95% confidence interval = 17.3-26.9 nM), and 57.0 nM (95% confidence interval = 44.2-73.4 nM) for IL-23-pSTAT3, type I IFN-pSTAT3, and IL-12-pSTAT4 pathways, respectively; zasocitinib showed no inhibition of Jak1/2/3. Simulated clinical concentrations of 30 mg zasocitinib once daily exceeded the TYK2 half-maximal inhibitory concentration for 24 hours, maintaining >90% daily inhibition, with no Jak1/2/3 inhibition. The distinct potent and selective inhibition profile of zasocitinib defines it as a next-generation TYK2 inhibitor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TYK2 KinaseProtein Kinase InhibitorsBenzamidesHumansSignal TransductionAdministration, OralAllosteric RegulationPhosphorylationSTAT3 Transcription FactorBridged-Ring CompoundsPyrimidines

Stichwörter der Autor:innen

Cytokine signalingImmune-mediated inflammatory diseaseTYK2Zasocitinib

Substanzen

TYK2 KinaseTYK2 protein, humanProtein Kinase Inhibitors11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,1…STAT3 protein, humanSTAT3 Transcription FactorBenzamidesBridged-Ring CompoundsPyrimidines

Autor:innen und Institutionen

  • Department of Quantitative Clinical Pharmacology, Takeda Development Center Americas, Cambridge, Massachusetts, USA. Electronic address: shailly.mehrotra@takeda.com.
  • Gastrointestinal and Inflammation Drug Discovery Unit, Takeda Development Center Americas, Cambridge, Massachusetts, USA.
  • Department of Quantitative Clinical Pharmacology, Takeda Development Center Americas, Cambridge, Massachusetts, USA.
  • Department of Quantitative Sciences, Takeda Development Center Americas, Cambridge, Massachusetts, USA.
  • Global Medical Affairs - Dermatology, Takeda Development Center Americas, Cambridge, Massachusetts, USA.
  • Gastroenterology and Inflammation Therapeutic Area, Takeda Development Center Americas, Cambridge, Massachusetts, USA.

Förderung

  • Takeda Pharmaceuticals America Inc

Zitieren

APA

Mehrotra, S., Sano, Y., Halkowycz, P., Wilson, E., Durairaj, C., Kong, K. F., Xia, G., Dunbar, F., Spector, T., Heap, G. A., Bunick, C. G., & McInnes, I. B. (2026). Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor. Journal of Investigative Dermatology, 146(1), 214-222.e7. https://doi.org/10.1016/j.jid.2025.05.014

Vancouver

Mehrotra S, Sano Y, Halkowycz P, Wilson E, Durairaj C, Kong KF, et al. Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor. Journal of Investigative Dermatology. 2026;146(1):214-222.e7. doi:10.1016/j.jid.2025.05.014

BibTeX
@article{Mehrotra2026,
  author = {Mehrotra, Shailly and Sano, Yasuyo and Halkowycz, Petro and Wilson, Elizabeth and Durairaj, Chandra and Kong, Kok-Fai and Xia, Guliang and Dunbar, Faith and Spector, Taylor and Heap, Graham A and Bunick, Christopher G and McInnes, Iain B},
  title = {Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor},
  journal = {Journal of Investigative Dermatology},
  year = {2026},
  volume = {146},
  number = {1},
  pages = {214--222.e7},
  doi = {10.1016/j.jid.2025.05.014}
}
Kostenlos starten →